Jones Financial Companies
KYTX icon

Jones Financial Companies’s Kyverna Therapeutics KYTX Stock Holding History

Jones Financial Companies’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289 Hold
37
– – ﹤0.01% 4566
2025
Q4 		$348 Buy
+37
New +$275 ﹤0.01% 4216
2025
Q2 		– Sell
-81
Closed -$162 – 4179
2025
Q1 		$162 Buy
+81
New +$239 ﹤0.01% 3603

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Jones Financial Companies's KYTX Position: Q1 2026 in Review

Jones Financial Companies held its Kyverna Therapeutics (KYTX) position steady in Q1 2026 at 37 shares worth $289. The position accounts for ﹤0.01% of the portfolio, ranked #4566.

Jones Financial Companies first reported a position in KYTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $348 in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Jones Financial Companies held 37 shares of Kyverna Therapeutics worth $289 as of Q1 2026.
  • Jones Financial Companies left its Kyverna Therapeutics share count unchanged in Q1 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4566 holding.
  • Jones Financial Companies first reported a position in Kyverna Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Jones Financial Companies's Kyverna Therapeutics position peaked at $348 in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.